Menu Search
Equities

Cell MedX Corp

CMXC:PKC

Cell MedX Corp

Actions
  • Price (USD)0.027
  • Today's Change-0.008 / -22.86%
  • Shares traded17.50k
  • 1 Year change-46.00%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 17:49 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Cell MedX Corp had revenues fall -100.00% from 2.76k to 0.00, though the company grew net income from a loss of 495.04k to a smaller loss of 142.49k.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-190.76%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2024, cash reserves at Cell MedX Corp fell by 54.88k. Cash Flow from Financing totalled 91.03k or -- of revenues. In addition the company used 145.90k for operations while cash used for investing totalled .
Cash flow per share-0.0009
Price/Cash flow per share--
Book value per share-0.0028
Tangible book value per share-0.0028
More ▼

Balance sheet in USDView more

Cell MedX Corp uses little or no debt in its capital structure.
Current ratio0.0529
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.